Tumor, Solid
63
20
23
20
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.9%
5 terminated out of 63 trials
80.0%
-6.6% vs benchmark
0%
0 trials in Phase 3/4
35%
7 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 20 completed trials
Clinical Trials (63)
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery
The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Standardized Nutritional Management of Pediatric Patients With Solid Tumors
TumorGlow Intraoperative Molecular Imaging (IMI)
Varian ProBeam Proton Therapy System Clinical Trial (Shandong)
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Immune Profiling for Cancer Immunotherapy Response
Varian ProBeam360° Proton Therapy System China Clinical Trial (Wuhan)
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab